GHActive

Will Shield blood test volume reach 210,000+ tests in FY2026?

Resolves February 28, 2027(325d)

IG: 0.80

Current Prediction

48%

Likely No

Model Agreement94%

Predictions9 runs

Last UpdatedApril 8, 2026

Why This Question Matters

Shield test volume is the most direct measure of commercial execution. All 8 lenses identified Shield as the primary thesis variable.

REVENUE_DURABILITYUNIT_ECONOMICS

Prediction Distribution

0%25%50%75%100%

opus

sonnet

haiku

Range: 45% – 50%Aggregate: 48%

Individual Predictions(9 runs)

opusRun 1

50%

Management guided to 210-225K which suggests internal visibility. However, novel screening test adoption is inherently unpredictable. Healthcare system integration is slower than consumer product adoption. Coin-flip reflecting genuine uncertainty.

Management guidance suggests visibilityHealthcare adoption unpredictableSystem integration is slow

opusRun 2

47%

Slightly below coin-flip. The DIVERGING narrative-reality gap identified by Myth Meter suggests Shield adoption may not match the optimistic TAM narrative. Physician behavior change requires time even with strong clinical data.

DIVERGING narrative gapPhysician behavior change takes timeTAM may exceed near-term reality

opusRun 3

48%

The 210K target is the low end of guidance. Management typically sets guidance they expect to meet. However, this is a new product category and first-year commercial guidance has higher miss rates than established products.

Low end of guidanceManagement expects to meetNew product category higher miss rate

sonnetRun 1

48%

Shield has product-market fit but scaling to 210K requires systemic adoption beyond early enthusiasts. Quest partnership helps but ramp takes time. Near coin-flip.

Product-market fit existsSystemic adoption neededQuest partnership still ramping

sonnetRun 2

45%

Medical adoption curves are typically S-shaped with slow initial uptake. FY2026 may still be in the early part of the curve. The 210K target could be aspirational for the first full commercial year.

S-shaped adoption curveEarly curve positionPossibly aspirational target

sonnetRun 3

50%

Management has consistently met or exceeded guidance across existing products. This execution track record supports confidence in the 210K target. But Shield is a new category with different dynamics.

Strong execution track recordNew category dynamicsBalanced assessment

haikuRun 1

48%

Management guidance suggests confidence. Healthcare adoption friction is real. Near coin-flip slightly favoring NO.

Guidance confidenceAdoption frictionSlight lean NO

haikuRun 2

47%

Novel screening test first-year volumes are hard to predict. 210K requires consistent high-volume quarters.

Hard to predictConsistent quarters neededBelow coin-flip

haikuRun 3

50%

Balanced. Management track record vs new product category uncertainty. Coin-flip.

Management track recordNew product uncertaintyCoin-flip

Resolution Criteria

Resolves YES if Guardant Health reports Shield test volumes of 210,000 or more for FY2026. Resolves NO if below 210,000 tests.

Resolution Source

Guardant Health FY2026 earnings release

Source Trigger

Shield quarterly test volumes are the primary commercial execution metric; management guided 210-225K annual tests

gravy-gaugeREVENUE_DURABILITYCRITICAL

View GH Analysis

Full multi-lens equity analysis